Key clinical point: A front-line chemotherapy-free induction-consolidation protocol with dasatinib and blinatumomab resulted in high survival and molecular response rates in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Major finding: The molecular response rate after blinatumomab cycle two was 60%.
Study details: The phase 2 D-ALBA study included 63 patients with Ph+ ALL.
Disclosures: Dr. Chiaretti reported membership on a board of directors or advisory committee for Pfizer, Incyte, Amgen, and Shire.
Chiaretti S et al. ASH 2019, Abstract 740.